Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P07384

UPID:
CAN1_HUMAN

ALTERNATIVE NAMES:
Calcium-activated neutral proteinase 1; Calpain mu-type; Calpain-1 large subunit; Cell proliferation-inducing gene 30 protein; Micromolar-calpain

ALTERNATIVE UPACC:
P07384; Q2TTR0; Q6DHV4

BACKGROUND:
The Calpain-1 catalytic subunit, recognized by its alternative names such as Calpain mu-type and Micromolar-calpain, is a calcium-regulated enzyme crucial for cellular dynamics. It engages in the limited proteolysis of key substrates, facilitating both cytoskeletal remodeling and the transduction of cellular signals.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Spastic paraplegia 76, a condition marked by progressive weakness and spasticity of the lower limbs, Calpain-1 emerges as a significant target for drug discovery. Exploring the therapeutic potential of modulating Calpain-1 activity offers a promising avenue for the development of novel treatments for this and possibly other related neurodegenerative disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.